Centogene N.V.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kim Stratton
- Full Time Employees
- 384
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Am Strande 7 Rostock Germany 18055
- IPO Date
- Nov 7, 2019
- CIK
- 0001757097
- Website
- centogene.com
- Similar Companies
- Business
- Centogene N.V. (CNTG) operates as a biotechnology company focused on rare and neurodegenerative diseases, integrating multiomic technologies including phenomics, genomics, transcriptomics, epigenomics, proteomics, and metabolomics with its proprietary CENTOGENE Biodatabank and CentoCard sample logistics system to deliver precision medicine solutions; core offerings span diagnostics services such as Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), next-generation sequencing (NGS) panels for over 3,800 genes and 19,000 total genes analyzed, customizable gene panels, reproductive genetics testing for early mutation detection, and CentoDx genomic knowledge management platform; pharmaceutical services include target and drug screening, clinical development support, market access, Biodatabank licenses, and insight reports for pharma partners. The company serves physicians, laboratories, hospitals, and pharmaceutical firms through distribution partners, targeting patients with hereditary conditions, rare diseases, and neurodegenerative disorders across segments encompassing clinical diagnostics and pharma solutions. Founded in 2006 and headquartered at Am Strande 7, Rostock, Germany, Centogene maintains a global footprint with operations and support in Europe, North America, Latin America (including Brazil), Middle East (including Dubai and Saudi Arabia via joint venture Genomics Innovations Company Limited/Lifera Omics), Asia-Pacific (including India), and additional locations in the US, Spain, and Serbia; it employs around 384 to 650 professionals and reported 2023 revenue of $52.5 million. In recent developments, Centogene signed a strategic transaction in November 2024 to sell its operating subsidiary Centogene GmbH, intercompany receivables, and related assets to an affiliate of Charme Capital Partners, a pan-European private equity firm, for EUR 8.7 million plus additional capital injection at closing expected in Q1 2025 to realign finances and drive growth; the deal relieves liabilities to senior lender Oxford Finance LLC and includes funding from its Saudi JV; earlier in October 2024, it launched a strategic partnership with Premier Research to support end-to-end rare disease clinical trials.
CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners
CENTOGENE Announces Voting Results of Extraordinary General Meeting
CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners
CENTOGENE Data on Novel Genetic Risk Factor for Parkinson's Disease in The Lancet Neurology
CENTOGENE Receives Delisting Notice From Nasdaq
CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson's Disease Cases Are Linked to Genetic Factors
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
CENTOGENE Receives Nasdaq Non-Compliance Notice
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
CENTOGENE Explores Strategic Alternatives
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
CENTOGENE Receives French Research Tax Credit Accreditation
CENTOGENE Announces Preliminary Full Year 2023 Revenue